Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Factors Affecting Drug Distribution: Physiological Barriers

Factors Affecting Drug Distribution: Physiological Barriers

Drug distribution in the body is intricately regulated by various physiological barriers that control the passage of substances. These include the capillary endothelial barrier, the blood-brain, blood-cerebrospinal fluid, blood-placental, and blood-testis barriers.
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...

Lysosomal Hydrolases

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...

Drug Binding to Blood Components

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A clinically feasible framework to estimate tau pathology and clinical-biological discordance in the Alzheimer's disease spectrum.

Alzheimer's research & therapy·2026

Same author

Taiwan Clinical Practice Guidelines for Myasthenia Gravis.

Acta neurologica Taiwanica·2026

Same author

ADAS-Cog11 performance as a surrogate of tau PET burden in an Asian Alzheimer's disease cohort.

Journal of Alzheimer's disease : JAD·2026

Same author

Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.

Neurology·2025

Same author

Neuronal-specific antibody in patients with multiple system atrophy and progressive supranuclear palsy.

Journal of the Formosan Medical Association = Taiwan yi zhi·2025

Same author

Visual interpretation of [<sup>18</sup>F]Florzolotau Tau-PET imaging for differentiating alzheimer's disease and progressive supranuclear palsy.

European journal of nuclear medicine and molecular imaging·2025

Search research articles

Related Experiment Video

Updated: Mar 24, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Dopamine transporter binding in Wilson's disease.

Chin-Chang Huang¹, Nai-Shin Chu, Tzu-Chen Yen

¹Department of Neurology, Chang Gung Memorial Hospital and University, Taipei, Taiwan.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques

|May 31, 2003

Summary

Wilson's disease (WD) patients can show normal presynaptic dopamine function despite MRI evidence of substantia nigra involvement. This suggests heterogeneity in WD, impacting treatment strategies for akinetic-rigid syndrome.

More Related Videos

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Published on: April 3, 2014

Related Experiment Videos

Last Updated: Mar 24, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra

Published on: September 8, 2021

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake

Published on: September 21, 2017

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Brain Slice Biotinylation: An Ex Vivo Approach to Measure Region-specific Plasma Membrane Protein Trafficking in Adult Neurons

Published on: April 3, 2014

Area of Science:

Neuroimaging
Neurology
Dopamine Pathway Research

Background:

Wilson's disease (WD) is characterized by T2-weighted MRI showing increased signal intensity in brain regions including the substantia nigra.
Poor levodopa response in WD suggests postsynaptic abnormalities, yet positron emission tomography studies indicate nigrostriatal presynaptic dopaminergic pathway involvement.

Observation:

A case of WD with akinetic-rigid syndrome presented with MRI-detected substantia nigra lesions.
Dopamine transporter (DAT) imaging revealed normal presynaptic nigrostriatal dopaminergic terminal function in this patient.

Findings:

Brain MRI findings in WD can coexist with a normal presynaptic dopaminergic pathway.
This challenges the assumption of universal presynaptic dopaminergic terminal dysfunction in all WD patients with akinetic-rigid syndrome.

Implications:

Highlights significant heterogeneity in Wilson's disease pathophysiology.
Suggests that presynaptic dopaminergic pathway integrity should be considered in WD patient assessment and treatment planning.
May necessitate re-evaluation of therapeutic approaches for WD patients exhibiting atypical imaging and functional findings.